EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Dose optimization of remimazolam as an adjunct to propofol for gastroscopy sedation: a randomized double-blind trial

Yijie Zhang, Shanshan Xia, Hai Wang, Hanbing Shen, Lian Fang, Yating Chen, Yuanyuan Pan, Nana Bao, Lili Yang, Yingchao Ye, Junlu Wang, Yunchang Mo

Frontiers in Pharmacology · 29.04.2026 · 17

DOI: 10.3389/fphar.2026.1782559 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Yijie Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Jinhua Affiliated Hospital of Wenzhou Medical University, Jinhua, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Propofol-based sedation for gastroscopy is effective but may cause dose-dependent cardiorespiratory depression; therefore, optimizing adjunct strategies to reduce propofol exposure is clinically important.

Methods

We conducted a prospective, single-center, randomized, double-blind, dose-response trial to evaluate the propofol-sparing effect of remimazolam during procedural sedation for gastroscopy. A total of 150 ASA I-II adults aged 18–59 years were randomly assigned to receive remimazolam 0, 0.05, 0.1, 0.15, or 0.2 mg·kg −1 , and propofol was titrated to achieve adequate sedation. The primary outcomes were the propofol effect-site EC50 and propofol requirement (mg·kg −1 ·min −1 ). Secondary outcomes included recovery profiles, post-anesthesia care unit (PACU) duration, and sedation-related adverse events.

Results

Remimazolam reduced the propofol EC50 in a dose-dependent manner, from 3.05 (95% CI, 2.88–3.21) μg·mL −1 at 0.05 mg·kg −1 to 1.47 (95% CI, 1.30–1.64) μg·mL −1 at 0.2 mg·kg −1 , and decreased propofol requirement from 0.587 ± 0.193 mg·kg −1 ·min −1 in the control group to 0.414 ± 0.121 mg·kg −1 ·min −1 at 0.1 mg·kg −1 and 0.298 ± 0.088 mg·kg −1 ·min −1 at 0.2 mg·kg −1 . Procedure duration and PACU duration did not differ significantly among groups, and the incidence of sedation-related adverse events was comparable.

Discussion

Adjunctive remimazolam provided a dose-dependent propofol-sparing effect during gastroscopy sedation. Among the tested doses, 0.1 mg·kg −1 appeared to offer a favorable balance between reduced propofol requirement and recovery profile, supporting its clinical feasibility under the conditions studied. Clinical Trial Registration Chinese Clinical Trial Registry, identifier ChiCTR2400094449.

Schlagwörter

Stichwörter der Autor:innen

EC50dose optimizationgastroscopyprocedural sedationpropofolrandomized controlled trialremimazolam

Autor:innen und Institutionen

  • Department of Anesthesiology, The Jinhua Affiliated Hospital of Wenzhou Medical University, Jinhua, China.
  • Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Anesthesiology, Wenzhou People's Hospital, Wenzhou, China.
  • Hepatobiliary Pancreatic Gastrointestinal Surgery, The Jinhua Affiliated Hospital of Wenzhou Medical University, Jinhua, China.

Zitieren

APA

Zhang, Y., Xia, S., Wang, H., Shen, H., Fang, L., Chen, Y., Pan, Y., Bao, N., Yang, L., Ye, Y., Wang, J., & Mo, Y. (2026). Dose optimization of remimazolam as an adjunct to propofol for gastroscopy sedation: a randomized double-blind trial. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1782559

Vancouver

Zhang Y, Xia S, Wang H, Shen H, Fang L, Chen Y, et al. Dose optimization of remimazolam as an adjunct to propofol for gastroscopy sedation: a randomized double-blind trial. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1782559

BibTeX
@article{Zhang2026,
  author = {Zhang, Yijie and Xia, Shanshan and Wang, Hai and Shen, Hanbing and Fang, Lian and Chen, Yating and Pan, Yuanyuan and Bao, Nana and Yang, Lili and Ye, Yingchao and Wang, Junlu and Mo, Yunchang},
  title = {Dose optimization of remimazolam as an adjunct to propofol for gastroscopy sedation: a randomized double-blind trial},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1782559}
}
Kostenlos starten →